SM-09419

N/A

Report date: 2022/10/21 15:47:24
NME

Base Information

Drug NameSM-09419
Drug Alias NameSM-09419 (Samumed)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionClk dual-specificity kinase inhibitorsWnt signalling pathway inhibitors
TargetsDual specificity protein kinase CLK
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiosplice Therapeutics IncBiosplice Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiosplice Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A